Posted by Michael Wonder on 24 Aug 2021
FDA approves expanded peripheral artery disease indication for Xarelto (rivaroxaban) plus aspirin to include patients after lower extremity revascularisation due to symptomatic peripheral artery disease
24 August 2021 - Xarelto is the first and only therapy indicated for both coronary artery disease and peripheral artery disease, now including peripheral artery disease patients post lower extremity revascularisation.
Janssen today announced that the U.S. FDA has approved an expanded peripheral artery disease indication for the Xarelto (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower extremity revascularisation due to symptomatic peripheral artery disease.
